Chromadex ( (CDXC) ) has provided an update.
ChromaDex Corporation reported a strong third quarter in 2024, with a remarkable 31% increase in net sales, reaching $25.6 million. The growth was fueled by increased sales of Niagen® ingredients, including a significant rise in pharmaceutical-grade Niagen, resulting in a record net income of $1.9 million and an adjusted EBITDA of $2.9 million. The company expanded its Niagen+ product line to over 100 wellness clinics and continues to foster scientific research and development, positioning itself for future growth and innovation.
Learn more about CDXC stock on TipRanks’ Stock Analysis page.
